Twist CEO sells 16,470 shares after option exercise
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a combination of option exercise and share sales in common stock.
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a combination of option exercise and share sales in common stock. She exercised employee stock options to acquire 16,470 shares at an exercise price of $8.82 per share, then sold 16,470 shares in multiple open‑market transactions at prices ranging from $65.3256 to $68.6141 per share. After these transactions, she directly owns 861,860 shares of Twist common stock. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on May 27, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 16,470 shares ($973K approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
16,470 shs ($1.12M)
Approx. gross sale proceeds
$1.12M
Approx. exercise cost
$145K
Approx. pre-tax spread
$973K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 16,470 | $0.00 | $0.00 |
| Exercise | Common Stock | 16,470 | $8.82 | $145K |
| Sale | Common Stock | 1,482 | $65.3256 | $97K |
| Sale | Common Stock | 900 | $66.8477 | $60K |
| Sale | Common Stock | 7,623 | $67.9508 | $518K |
| Sale | Common Stock | 6,465 | $68.6141 | $444K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 140,389 contracts for 64,950 underlying shares (Direct);
Common Stock — 846,872 shares (Direct)
Footnotes (10)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
- F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.820 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.240 to $67.210 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $67.240 to $68.2375 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $68.240 to $69.190 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F6. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F7. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F8. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F9. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
- F10. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Key Figures
Shares sold: 16,470 shares
Sale prices: $65.3256–$68.6141 per share
Options exercised: 16,470 shares at $8.82/share
+3 more
6 metrics
Shares sold
16,470 shares
Open-market sales on May 28, 2026
Sale prices
$65.3256–$68.6141 per share
Reported weighted average prices for sales
Options exercised
16,470 shares at $8.82/share
Employee stock option exercise into common stock
Post-transaction holdings
861,860 shares
Common stock directly owned after transactions
Remaining option grant
64,950 underlying shares at $67.85
Employee stock option expiring August 31, 2030
10b5-1 plan adoption
May 27, 2025
Date Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average sales price per share, performance stock options, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)" with underlying security title Common Stock"
performance stock options financial
"Represents performance stock options granted to the reporting person on September 1, 2020..."
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for the M code transactions"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did Twist Bioscience (TWST) CEO Emily Leproust exercise?
She exercised employee stock options for 16,470 shares at $8.82 per share. The exercised options were "Employee Stock Option (right to buy)" awards, converting into 16,470 shares of Twist Bioscience common stock in a derivative exercise transaction.
What remaining stock options does Twist Bioscience (TWST) CEO Emily Leproust hold?
She holds an option covering 64,950 underlying shares at $67.85 per share. The derivative holdings table shows an employee stock option, exercisable for 64,950 shares of common stock, with a August 31, 2030 expiration date.
What were the price ranges for Emily Leproust’s Twist Bioscience (TWST) stock sales?
The reported sales occurred between about $65.3256 and $68.6141 per share. Individual sale lines show weighted average prices of $65.3256, $66.8477, $67.9508, and $68.6141 per share for the open‑market transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
